<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with ring sideroblasts and <z:hpo ids='HP_0001894'>thrombocytosis</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>-T) are difficult to treat because the cytoreductive treatment might be beneficial for the <z:hpo ids='HP_0001894'>thrombocytosis</z:hpo> component but harmful for the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e> component </plain></SENT>
<SENT sid="1" pm="."><plain>As lenalidomide has shown to be efficacious in both <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> and myeloproliferative <z:hpo ids='HP_0002664'>neoplasms</z:hpo>, we have treated 2 RARS-T patients, who were transfusion dependent, with lenalidomide </plain></SENT>
<SENT sid="2" pm="."><plain>We report the results of lenalidomide treatment in these patients and show that lenalidomide has clinical activity in this <z:e sem="disease" ids="C0678236" disease_type="Disease or Syndrome" abbrv="">rare disorder</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Both patients became transfusion independent, and 1 of the patients attained indeed a complete molecular remission </plain></SENT>
</text></document>